A role for Fli-1 in B cell proliferation: Implications for SLE pathogenesis

Clinical Immunology

Volumn 129, Issue 1, 2008, Pages 19-30

  Bradshaw, Sarah ^a   Zheng, W Jim ^b   Tsoi, Lam C ^b   Gilkeson, Gary ^a,c   Zhang, Xian K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

B cell; BCR; Fli 1; IL12; NFAT; Proliferation; SLE; TLR; TNF beta

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; INTERLEUKIN 12P35; LECTIN RECEPTOR; MITOGENIC AGENT; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR NFAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROL GROUP; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL MOUSE; FEMALE; MALE; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; WILD TYPE;

ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION; INTERLEUKIN-12 SUBUNIT P35; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NFATC TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEIN C-FLI-1; RECEPTORS, ANTIGEN, B-CELL; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; UP-REGULATION;

EID: 51249113631     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.05.010     Document Type: Article

References (84)

1. Jacobson D.L., Gange S.J., Rose N.R., and Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84 (1997) 223-243
2. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., Domenech I., Aydintug A.O., Jedryka-Goral A., and de Ramon E. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72 (1993) 113-124
3. McCarty D.J., Manzi S., Medsger Jr. T.A., Ramsey-Goldman R., LaPorte R.E., and Kwoh C.K. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum. 38 (1995) 1260-1270
4. Richardson B., Scheinbart L., Strahler J., Gross L., Hanash S., and Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33 (1990) 1665-1673
5. Mishra N., Brown D.R., Olorenshaw I.M., and Kammer G.M. Trichostatin a reverses skewed expression of Cd154, Interleukin-10, and Interferon-gamma gene and protein expression in lupus T cells. Proc. Natl. Acad. Sci. U S A 98 (2001) 2628-2633
6. Reilly C.M., Mishra N., Miller J.M., Joshi D., Ruiz P., Richon V.M., Marks P.A., and Gilkeson G.S. Modulation of renal disease in Mrl/Lpr mice by suberoylanilide hydroxamic acid. J. Immunol. 173 (2004) 4171-4178
7. Eisenberg R.A., Craven S.Y., Warren R.W., and Cohen P.L. Stochastic control of anti-Sm autoantibodies in Mrl/Mp-Lpr/Lpr mice. J. Clin. Invest. 80 (1987) 691-697
8. James J.A., Kaufman K.M., Farris A.D., Taylor-Albert E., Lehman T.J., and Harley J.B. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J. Clin. Invest. 100 (1997) 3019-3026
9. Fawaz-Estrup F. Human parvovirus infection: rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA positivity, and possible onset of systemic lupus erythematosus. J. Rheumatol. 23 (1996) 1180-1185
10. Geier D.A., and Geier M.R. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 38 (2005) 295-301
11. Kowal C., Weinstein A., and Diamond B. Molecular mimicry between bacterial and self antigen in a patient with systemic lupus erythematosus. Eur. J. Immunol. 29 (1999) 1901-1911
12. Conrad K., Mehlhorn J., Luthke K., Dorner T., and Frank K.H. Systemic lupus erythematosus after heavy exposure to quartz dust in uranium mines: clinical and serological characteristics. Lupus 5 (1996) 62-69
13. Kilburn K.H., and Warshaw R.H. Prevalence of symptoms of systemic lupus erythematosus (Sle) and of fluorescent antinuclear antibodies associated with chronic exposure to trichloroethylene and other chemicals in well water. Environ. Res. 57 (1992) 1-9
14. Satoh M., Hamilton K.J., Ajmani A.K., Dong X., Wang J., Kanwar Y.S., and Reeves W.H. Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in Sjl mice treated with Pristane. J. Immunol. 157 (1996) 3200-3206
15. Sarzi-Puttini P., Atzeni F., Capsoni F., Lubrano E., and Doria A. Drug-induced lupus erythematosus. Autoimmunity 38 (2005) 507-518
16. Timbrell J.A., Facchini V., Harland S.J., and Mansilla-Tinoco R. Hydralazine-induced lupus: is there a toxic metabolic pathway?. Eur. J. Clin. Pharmacol. 27 (1984) 555-559
17. Fauci A.S., and Moutsopoulos H.M. Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum. 24 (1981) 577-583
18. Suzuki N., and Sakane T. Induction of excessive B cell proliferation and differentiation by an in vitro stimulus in culture in human systemic lupus erythematosus. J. Clin. Invest. 83 (1989) 937-944
19. Liossis S.N., Kovacs B., Dennis G., Kammer G.M., and Tsokos G.C. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J. Clin. Invest. 98 (1996) 2549-2557
20. Klemsz M.J., Maki R.A., Papayannopoulou T., Moore J., and Hromas R. Characterization of the Ets oncogene family member, Fli-1. J. Biol. Chem. 268 (1993) 5769-5773
21. Rao V.N., Ohno T., Prasad D.D., Bhattacharya G., and Reddy E.S. Analysis of the DNA-binding and transcriptional activation functions of human Fli-1 protein. Oncogene 8 (1993) 2167-2173
22. Zhang L., Lemarchandel V., Romeo P.H., Ben-David Y., Greer P., and Bernstein A. The Fli-1 proto-oncogene, involved in erythroleukemia and Ewing's sarcoma, encodes a transcriptional activator with DNA-binding specificities distinct from other Ets family members. Oncogene 8 (1993) 1621-1630
23. Athanasiou M., Mavrothalassitis G., Sun-Hoffman L., and Blair D.G. Fli-1 is a suppressor of erythroid differentiation in human hematopoietic cells. Leukemia 14 (2000) 439-445
24. Fisher R.J., Mavrothalassitis G., Kondoh A., and Papas T.S. High-affinity DNA-protein interactions of the cellular ETS1 protein: the determination of the ETS binding motif. Oncogene 6 (1991) 2249-2254
25. Spyropoulos D., Pharr P., Lavenburg K., Jackers P., Papas T., Ogawa M., and Watson D.K. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol. Cell. Biol. 20 (2000) 5643-5652
26. Baud V., Lipinski M., Rassart E., Poliquin L., and Bergeron D. The human homolog of the mouse common viral integration region, FLI1, maps to 11q23-q24. Genomics 11 (1991) 223-224
27. Hart A., Melet F., Grossfeld P., Chien K., Jones C., Tunnacliffe A., Favier R., and Bernstein A. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 13 (2000) 167-177
28. Breton-Gorius J., Favier R., Guichard J., Cherif D., Berger R., Debili N., Vainchenker W., and Douay L. A new congenital dysmegakaryopoietic thrombocytopenia (Paris-Trousseau) associated with giant platelet alpha-granules and chromosome 11 deletion at 11q23. Blood 85 (1995) 1805-1814
29. Raslova H., Komura E., Le Couedic J.P., Larbret F., Debili N., Feunteun J., Danos O., Albagli O., Vainchenker W., and Favier R. Fli1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J. Clin. Invest. 114 (2004) 77-84
30. Rivera R.R., Stuiver M.H., Steenbergen R., and Murre C. Ets proteins: new factors that regulate immunoglobulin heavy-chain gene expression. Mol. Cell. Biol. 13 (1993) 7163-7169
31. Zhang L., Eddy A., Teng Y.T., Fritzler M., Kluppel M., Melet F., and Bernstein A. An immunological renal disease in transgenic mice that overexpress Fli-1, a member of the Ets family of transcription factor genes. Mol. Cell. Biol. 15 (1995) 6961-6970
32. Georgiou P., Maroulakou I., Green J., Dantis P., Romanospica V., Kottaridis S., Lautenberger J., Watson D.K., Papas T., Fischinger P., and Bhat N. Expression of Ets family of genes in systemic lupus erythematosus and Sjogren's syndrome. Int. J. Oncol. 9 (1996) 9-18
33. Zhang X.K., Gallant S., Molano I., Moussa O.M., Ruiz P., Spyropoulos D.D., Watson D.K., and Gilkeson G. Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. J. Immunol. 173 (2004) 6481-6489
34. Qiagen, Dneasy Blood and Tissue Handbook. (updated 2006 July) http://www1.qiagen.com/literature/handbooks (accessed 2007 Dec 28).
35. Miltenyi Biotec, Cd43 (Ly-48) Microbeads, Mouse Datasheet. (updated 2006) http://www.miltenyibiotec.com/download/datasheets/53/DS130-049-801 (accessed 2007 Dec 28).
36. Miltenyi Biotec, Cd90 (Thy1.2) Microbeads Datasheet. http://www.miltenyibiotec.com/download/datasheets/46/DS130-049-101.pdf (accessed 2008 Jan 21).
37. Melchers F., Braun V., and Galanos C. The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen. J. Exp. Med. 142 (1975) 473-482
38. Peden-Adams M., Alonso K., Godard C., Skipper S., Mashburn W., Hoover J., Charbonneau C., Henshel D., and Dickerson R. Effects of environmentally relevant concentrations of 2,3,7,8-Tcdd on domestic chicken immune function and Cyp450 activity: F1 generation and egg injection studies. Chemosphere 37 (1998) 1923-1939
39. Dziarski R. Studies on the mechanism of peptidoglycan- and lipopolysaccharide-induced polyclonal activation. Infect. Immun. 35 (1982) 507-514
40. eBioscience, Intracellullar Immunofluorescent Staining for Flow Cytometry. http://www.ebioscience.com/ebioscience/appls/FCI.htm (accessed 2008 Jan 4).
41. eBioscience, Elisa, Cytokine Antibody Pairs. http://www.ebioscience.com/ebioscience/appls/ELISApr.htm (accessed 2008 Jan 4).
42. Invitrogen, Guides: Linnea Protocols: Nucleic Acid Purification and Analysis: Isolation of Rna Using Trizol Reagent. http://www.invitrogen.com (accessed 2007 Dec 31).
43. Bio-Rad Laboratories, Life Science Research: Literature/Software: Smartspec Plus Spectrophotometer Instruction Manual. http://www.bio-rad.com (accessed 2007 Dec 31).
44. Invitrogen, Superscript Indirect Rna Amplification System User Manual. (updated 2006 Aug 9) http://www.invitrogen.com/content/sfs/manuals/superscript_indirecte_rnaamp_man.pdf (accessed 2007 Dec 31).
45. SuperArray Bioscience, Rt2 Profiler Pcr Array System User Manual. (updated 2007 Nov 30) http://www.superarray.com/manual/pcrarray.pdf (accessed 2007 Dec 31).
46. SuperArray Bioscience, Rt2 Rna Qc Pcr Arrays User Manual. (updated 2007 Aug 31) http://www.superarray.com/manual/rnaqcplate.pdf (accessed 2007 Dec 31).
47. SuperArray Bioscience, Rt2 Qpcr Primer Assays User Manual. (updated 2007 Jun 22) http://www.superarray.com/manual/realtimePCR.pdf (accessed 2007 Dec 31).
48. Mao L., and Zheng W.J. Combining comparative genomics with de novo motif discovery to identify human transcription factor DNA-binding motifs. BMC Bioinformatics 7 Suppl 4 (2006) S21
49. Mdframe: A Computational Framework for the Automatic Identification of Human Regulatory Motifs. http://genomebioinfo.musc.edu/MDframe.html (accessed 2007 Dec 31).
50. Andrews B.S., Eisenberg R.A., Theofilopoulos A.N., Izui S., Wilson C.B., McConahey P.J., Murphy E.D., Roths J.B., and Dixon F.J. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148 (1978) 1198-1215
51. Dixon F.J., Andrews B.S., Eisenberg R.A., McConahey P.J., Theofilopoulos A.N., and Wilson C.B. Etiology and pathogenesis of a spontaneous lupus-like syndrome in mice. Arthritis Rheum. 21 (1978) S64-S67
52. Parkhouse R.M., Preece G., Sutton R., Cordell J.L., and Mason D.Y. Relative expression of surface Igm, Igd and the Ig-associating alpha(Mb-1) and beta(B-29) polypeptide chains. Immunology 76 (1992) 535-540
53. Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas R.M., and Wagner H. Bacterial Cpg-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32 (2002) 1958-1968
54. Means T.K., and Luster A.D. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann. N. Y. Acad Sci. 1062 (2005) 242-251
55. Leifer C.A., Kennedy M.N., Mazzoni A., Lee C., Kruhlak M.J., and Segal D.M. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J. Immunol. 173 (2004) 1179-1183
56. Dasari P., Nicholson I.C., Hodge G., Dandie G.W., and Zola H. Expression of toll-like receptors on B lymphocytes. Cell Immunol. 236 (2005) 140-145
57. Eaton-Bassiri A., Dillon S.B., Cunningham M., Rycyzyn M.A., Mills J., Sarisky R.T., and Mbow M.L. Toll-like receptor 9 can be expressed at the cell surface of distinct populations of tonsils and human peripheral blood mononuclear cells. Infect. Immun. 72 (2004) 7202-7211
58. Raveche E.S., Steinberg A.D., DeFranco A.L., and Tjio J.H. Cell cycle analysis of lymphocyte activation in normal and autoimmune strains of mice. J. Immunol. 129 (1982) 1219-1226
59. Kawanishi H., and Joseph K. Effects of phorbol myristate and ionomycin on in vitro growth of aged Peyer's patch T and B cells. Mech. Ageing Dev. 65 (1992) 289-300
60. Frasca D., Nguyen D., Riley R.L., and Blomberg B.B. Effects of aging on proliferation and E47 transcription factor activity induced by different stimuli in murine splenic B cells. Mech. Ageing Dev. 124 (2003) 361-369
61. Papadimitraki E.D., Choulaki C., Koutala E., Bertsias G., Tsatsanis C., Gergianaki I., Raptopoulou A., Kritikos H.D., Mamalaki C., Sidiropoulos P., and Boumpas D.T. Expansion of Toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 54 (2006) 3601-3611
62. Maier H., Ostraat R., Parenti S., Fitzsimmons D., Abraham L.J., Garvie C.W., and Hagman J. Requirements for selective recruitment of Ets proteins and activation of mb-1/Ig-alpha gene transcription by Pax-5 (BSAP). Nucleic Acids Res. 31 (2003) 5483-5489
63. Czuwara-Ladykowska J., Shirasaki F., Jackers P., Watson D.K., and Trojanowska M. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J. Biol. Chem. 276 (2001) 20839-20848
64. Darby T.G., Meissner J.D., Ruhlmann A., Mueller W.H., and Scheibe R.J. Functional interference between retinoic acid or steroid hormone receptors and the oncoprotein Fli-1. Oncogene 15 (1997) 3067-3082
65. Huang X., Hua J., Shen N., and Chen S. Dysregulated expression of Interleukin-23 and Interleukin-12 subunits in systemic lupus erythematosus patients. Mod. Rheumatol. 17 (2007) 220-223
66. Houssiau F.A., Mascart-Lemone F., Stevens M., Libin M., Devogelaer J.P., Goldman M., and Renauld J.C. Il-12 inhibits in vitro immunoglobulin production by human lupus peripheral blood mononuclear cells (PBMC). Clin. Exp. Immunol. 108 (1997) 375-380
67. Tyrrell-Price J., Lydyard P.M., and Isenberg D.A. The effect of Interleukin-10 and of Interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 124 (2001) 118-125
68. Hagiwara E., Okubo T., Aoki I., Ohno S., Tsuji T., Ihata A., Ueda A., Shirai A., Okuda K., Miyazaki J., and Ishigatsubo Y. Il-12-encoding plasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. Cytokine 12 (2000) 1035-1041
69. Airoldi I., Di Carlo E., Banelli B., Moserle L., Cocco C., Pezzolo A., Sorrentino C., Rossi E., Romani M., Amadori A., and Pistoia V. The Il-12rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J. Clin. Invest. 113 (2004) 1651-1659
70. Kowalczyk D., Mytar B., and Zembala M. Cytokine production in transient hypogammaglobulinemia and isolated IgA deficiency. J. Allergy Clin. Immunol. 100 (1997) 556-562
71. Lee S.H., Park S.H., Min J.K., Kim S.I., Yoo W.H., Hong Y.S., Park J.H., Cho C.S., Kim T.G., Han H., and Kim H.Y. Decreased tumour necrosis factor-beta production in Tnfb*2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus 6 (1997) 603-609
72. Wu X., and Peng S.L. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 54 (2006) 336-342
73. Venkataraman L., Francis D.A., Wang Z., Liu J., Rothstein T.L., and Sen R. Cyclosporin-a sensitive induction of Nf-at in murine B cells. Immunity 1 (1994) 189-196
74. Healy J.I., Dolmetsch R.E., Lewis R.S., and Goodnow C.C. Quantitative and qualitative control of antigen receptor signalling in tolerant B lymphocytes. Novartis Found. Symp. 215 (1998) 137-144 discussion 144-5, 186-90
75. Yoshida H., Nishina H., Takimoto H., Marengere L.E., Wakeham A.C., Bouchard D., Kong Y.Y., Ohteki T., Shahinian A., Bachmann M., Ohashi P.S., Penninger J.M., Crabtree G.R., and Mak T.W. The transcription factor Nf-Atc1 regulates lymphocyte proliferation and Th2 cytokine production. Immunity 8 (1998) 115-124
76. Buchholz M., Schatz A., Wagner M., Michl P., Linhart T., Adler G., Gress T.M., and Ellenrieder V. Overexpression of C-Myc in pancreatic cancer caused by ectopic activation of Nfatc1 and the Ca2+/calcineurin signaling pathway. Embo J. 25 (2006) 3714-3724
77. Fu L., Lin-Lee Y.C., Pham L.V., Tamayo A., Yoshimura L., and Ford R.J. Constitutive Nf-Kappab and Nfat activation leads to stimulation of the Blys survival pathway in aggressive B-cell lymphomas. Blood 107 (2006) 4540-4548
78. Kneitz C., Goller M., Tony H., Simon A., Stibbe C., Konig T., Serfling E., and Avots A. The Cd23b promoter is a target for Nf-at transcription factors in B-CLL cells. Biochim. Biophys. Acta. 1588 (2002) 41-47
79. Bansal A., Roberts T., Hay E.M., Kay R., Pumphrey R.S., and Wilson P.B. Soluble Cd23 levels are elevated in the serum of patients with primary Sjogren's syndrome and systemic lupus erythematosus. Clin. Exp. Immunol. 89 (1992) 452-455
80. Brizard A., Morel F., Lecron J.C., Dreyfus B., Brizard F., Barra A., and Preud'homme J.L. Proliferative response of B chronic lymphocytic leukemia lymphocytes stimulated with Il2 and soluble Cd23. Leuk. Lymphoma 14 (1994) 311-318
81. Klashman D.J., Martin R.A., Martinez-Maza O., and Stevens R.H. In vitro regulation of B cell differentiation by Interleukin-6 and soluble Cd23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells. Arthritis Rheum. 34 (1991) 276-286
82. Swendeman S.L., and Thorley-Lawson D. Soluble Cd23/Blast-2 (S-Cd23/Blast-2) and its role in B cell proliferation. Curr. Top Microbiol. Immunol. 141 (1988) 157-164
83. Fournier S., Rubio M., Delespesse G., and Sarfati M. Role for low-affinity receptor for Ige (Cd23) in normal and leukemic B-cell proliferation. Blood 84 (1994) 1881-1886
84. Militi S., Chiapparino C., Testa U., Carminati P., De Santis R., and Serlupi-Crescenzi O. Role of Il-6 and Cd23 in the resistance to growth arrest and apoptosis in Lcl41 B lymphoma cells. Cytokine 31 (2005) 314-323